title: Impact of 4-methylbenzylidene camphor, daidzein, and estrogen on intact and osteotomized bone in osteopenic rats.
abstract: The study investigated the influence of 4-methylbenzylidene camphor (4-MBC), daidzein, and estradiol-17β-benzoate (E(2)) on either intact or osteotomized cancellous bone in ovariectomized (Ovx) rats. Three-month old Ovx rats were fed with soy-free (SF) diet over 8 weeks; thereafter, bilateral transverse metaphyseal osteotomy of tibia was performed and rats were divided into groups: rats fed with SF diet and SF diet supplemented with 4-MBC (200 mg), daidzein (50 mg), or E(2) (0.4 mg) per kilogram body weight. After 5 or 10 weeks, computed tomographical, biomechanical, histological, and ashing analyses were performed in lumbar spine and tibia of 12 rats from each group. 4-MBC and E(2) improved bone parameters in lumbar spine and tibia, were not favorable for osteotomy healing, and decreased serum osteocalcin level. However, daidzein improved bone parameters to a lesser extent and facilitated osteotomy healing. For lumbar spine, the bone mineral density was 338±9, 346±5, 361±6, and 360±5 mg/cm(3) in SF, daidzein, 4-MBC, and E(2), respectively, after 10 weeks. For tibia, the yield load was 98±5, 114±3, 90±2, and 52±4 N in SF, daidzein, 4-MBC, and E(2), respectively, after 10 weeks. Serum daidzein was 54±6 ng/ml in daidzein group and equol was not detected. Alp and Igf1 genes were down-regulated in callus after daidzein and E(2) compared with 4-MBC (week 5). The response of bone tissue and serum markers of bone metabolism could be ordered: daidzein<4-MBC<E(2). Treatments were more effective after 5 vs 10 weeks. In SF group, bone structure was impaired after 5 weeks and improved after 10 weeks probably due to adaptation mechanisms to osteoporosis. In conclusion, it is conceivable that 4-MBC may improve bone tissue in osteoporotic organisms; osteoporotic patients with fractures could benefit from daidzein treatment.
authors.affiliation: Department of Trauma Surgery and Reconstructive Surgery, University of Goettingen, Germany. komrakova@yahoo.com
authors.forename: Marina
authors.initials: M
authors.lastname: Komrakova
authors.forename: Stephan
authors.initials: S
authors.lastname: Sehmisch
authors.forename: Mohammad
authors.initials: M
authors.lastname: Tezval
authors.forename: Ulrich
authors.initials: U
authors.lastname: Schmelz
authors.forename: Holm
authors.initials: H
authors.lastname: Frauendorf
authors.forename: Thomas
authors.initials: T
authors.lastname: Grueger
authors.forename: Thomas
authors.initials: T
authors.lastname: Wessling
authors.forename: Carolin
authors.initials: C
authors.lastname: Klein
authors.forename: Miriam
authors.initials: M
authors.lastname: Birth
authors.forename: Klaus M
authors.initials: KM
authors.lastname: Stuermer
authors.forename: Ewa K
authors.initials: EK
authors.lastname: Stuermer
mesh_terms: D000135:Acid Phosphatase / Q000235:genetics; D000469:Alkaline Phosphatase / Q000097:blood / Q000235:genetics; D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism / Q000601:surgery; D002146:Bony Callus / Q000187:drug effects / Q000378:metabolism; D002164:Camphor / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004032:Diet; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D007527:Isoenzymes / Q000235:genetics; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology*; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D015675:Osteocalcin / Q000097:blood / Q000235:genetics; D010027:Osteotomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000071681:Tartrate-Resistant Acid Phosphatase; D013977:Tibia / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D004967:Estrogens; D007527:Isoenzymes; D007529:Isoflavones; C519530:insulin-like growth factor-1, mouse; D015675:Osteocalcin; C004742:daidzein; D007334:Insulin-Like Growth Factor I; D002164:Camphor; C038939:enzacamene; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase